@article{3220487,
    title = "Pancreatic cancer and oligonucleotide therapy: Exploring novel therapeutic options and targeting chemoresistance: Nucleotide therapy in pancreatic cancer",
    author = "Papaefthymiou, A. and Doukatas, A. and Galanopoulos, M.",
    journal = "Clinics and Research in Hepatology and Gastroenterology",
    year = "2022",
    volume = "46",
    number = "5",
    publisher = "Elsevier Masson s.r.l.",
    issn = "2210-7401",
    doi = "10.1016/j.clinre.2022.101911",
    keywords = "DNA;  microRNA, biogenesis;  clinical trial (topic);  drug delivery system;  drug resistance;  gene function;  gene targeting;  gene therapy;  human;  molecularly targeted therapy;  nonhuman;  oligonucleotide therapy;  oncogene;  pancreas cancer;  Review;  tumor growth",
    abstract = "Pancreatic cancer (PC) represents a malignancy with increased mortality rate, as less than 10% of patients survive for 5 years after diagnosis. Current evolution in basic sciences has revealed promising results by decrypting genetic loci vulnerable to mutations, as potential targets of novel treatment choices. In this regard, the “Oligonucleotide therapeutics”, based on synthetic nucleotides, modify the function and expression of their targets. Antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNAs (miRNAs), aptamers, CpG oligodeoxynucleotides and decoys comprise the main representatives of this emerging technology, by regulating oncogenes’ expression, restoring DNA repairment mechanisms, sensitizing cancer cells in chemotherapy, and inhibiting PC progress. A plethora of genetic treatment molecules and respective targets have been described and are currently studied, thus providing a broad range of probable pharmaceutical options. This narrative review illuminates the main parameters of genetic treatment molecules for PC and underlines their deficiencies, to clarify the upcoming future and trigger further investigation in PC management. © 2022 Elsevier Masson SAS"
}